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Abstract: Breast cancer is the most common malignancy in women worldwide and causes great 
economic burden. The aim of this paper is to present the available clinical and pharmacoeconomic 
evidence associated with different therapies for breast cancer. As significant progress was made 
in recent years and there are many alternative treatments, which are indicated according to the 
stage and the type of the disease, the age and health status of patient, and vary from surgery 
to hormonal treatment and chemotherapy. A broad literature review was undertaken and the 
paper presents the evidence available regarding the effectiveness and cost-effectiveness of the 
alternative options. Despite the high cost of most therapies and perceptions that treatments 
in this area may not be cost-effective, due to a combination of high costs and short survival, 
based on the literature review treatment options for breast cancer are in general deemed to be 
cost-effective. Time horizon, stage of the disease, patient age, therapy onset, benefit duration 
and time to recurrence may influence the results. Pharmacoeconomic analyses of alternative 
therapy options will improve decision-making and will help to optimize the use of scarce health 
care resources allocated to the care of breast cancer patients.
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Introduction
Breast cancer is the uncontrolled, abnormal growth of malignant breast tissue. It is the 
second most common nonskin cancer, with approximately 430,000 cases occurring 
each year in Europe.1 It is also the second leading cause of cancer-related death in 
women in the Western world after lung cancer,2 with about 132,000 deaths each year 
and a five-year overall survival of 79.5%.3
Current treatment options for breast cancer depend on disease characteristics 
(ie, stage, grade, Her-2 status, number of positive lymph nodes, hormone receptor status 
of the tumor) and on patient characteristics (such as age and menopausal status).
This paper aims at incorporating two distinct, yet important, features of oncology. 
Firstly, clinical concepts related to the treatment of breast cancer with hormone therapy 
and chemotherapy and, secondly, a pharmacoeconomic evaluation of the various 
approaches to the treatment of this common disease.
Epidemiology
Globally, breast cancer incidence rates are highest in North America and northern 
Europe, and lowest in Asia and Africa.4 Incidence rates in Japan and urban China have 
been rising in recent years. These international differences are thought to be related 
to societal changes occurring during industrialization (eg, changes in fat intake, body ClinicoEconomics and Outcomes Research 2010:2 48
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weight, age at menarche, and/or lactation, and reproductive 
patterns, such as fewer pregnancies and later age at first 
birth).
The lifetime probability of developing breast cancer is 
one in six overall (one in eight for invasive disease). Previ-
ous breast cancer, early menarche, late menopause, hormone 
replacement therapy, oral contraception, obesity, and alcohol 
consumption are associated with an increased risk of breast 
cancer. Although the majority of breast cancer cases occur 
in women who have no family history of the disease, family 
history and genetic predisposition also play an important 
role, because women who carry mutations of breast cancer 
susceptibility genes (BRCA1 or 2) are at a higher risk of 
developing breast cancer.5
The incidence of breast cancer increases rapidly with age 
during the reproductive years and then increases at a slower 
rate after about age 50, the average age at menopause. The 
cumulative incidence of breast cancer among women in 
Europe and North America is about 2.7% by age 55, about 
5.0% by age 65, and about 7.7% by age 75.6 Incidence rates 
are high in more developed countries, whereas rates in less 
developed countries are low but increasing.7
About 20% of all breast cancer cases occur in women 
younger than 50 years of age (premenopausal) and 60% of 
these cases are estrogen receptor-positive, compared with 
80% being estrogen receptor-positive in women older than 
50 years (postmenopausal).8 Breast tissue contains receptors 
for the female hormones estrogen and progesterone. These 
receptors allow the breast tissue to grow or change in response 
to changing levels of those hormones.
Breast cancer is a disease with a great epidemiologic 
and economic burden. The total cost of breast cancer 
includes not only the medical cost (ie, cost of screening, 
prevention, pharmaceutical treatment, surgical intervention, 
and palliative care) but also the indirect cost of the disease in 
terms of lost productivity and premature deaths, given that 
a significant percentage of the prevalence of breast cancer 
affecting women younger than 50 years of age.
Economic burden
The majority of studies that report the financial burden 
of breast cancer take into account the payer’s perspective, 
whereas the estimation of the societal cost of the disease 
is less commonly investigated. However, estimations of the 
total cost show that the direct cost is the smallest contributor 
to the total cost per patient, being dependent on the stage of 
the disease, the therapeutic intervention, and the patient’s 
age. Evidence from multiple studies has shown that the cost 
increases with the stage of the disease and age. In addition, 
differences in the cost per patient may also arise from alter-
native therapeutic schemes.
A review of the published studies of the cost of illness 
arising from breast cancer in the US concluded that the 
lifetime cost per patient varied between US$20,000 and 
US$100.000, with chemotherapy being the greatest driver 
of the total direct cost.9 A more recent study regarding the 
assessment of cost and resource utilization of breast cancer 
patients in US concluded that the mean monthly cost per 
patient was US$2,896, driven mainly by costs attributable 
to hospitalization, and followed by pharmacotherapy costs, 
and costs of surgical interventions.10 In California the total 
economic cost of breast cancer (indirect cost was included) 
was US$1.43 billion in 2001.11
In Sweden, the findings of a study that attempted to esti-
mate the cost of breast cancer confirmed, as expected, that an 
increased stage of disease translates into increased resource 
use and cost. Specifically, the annual total cost for patients 
with metastatic breast cancer was US$46,500. However, 
the researchers concluded that the indirect cost was lower 
for patients older than 65 years.12 This finding can be partly 
explained by the fact that people younger than 65 years are 
still working, so that the cost of lost productivity due to sick 
leave, early retirement, and premature mortality is greater.13
The treatment of metastases is also a significant 
contributor to the total cost of breast cancer.14,15 In the US 
it was estimated that the mean total cost of a metastatic 
breast cancer patient was almost nine times greater than 
for a noncancer patient.16 Finally, the economic burden of 
surviving breast cancer17 or breast cancer recurrence18 is also 
of great importance, mostly as regards the overuse of medical 
resources for followup.
Efficacy of therapy
Surgical treatment
Surgery is the cornerstone of management of early breast 
cancer. Breast cancer surgery has significantly evolved 
during the last decades. The operation evolved from 
radical mastectomy to modified radical mastectomy and to 
“skin-sparing” mastectomy, introduced in 1991.19 The intro-
duction of radiotherapy (RT) and its success in eliminating 
subclinical foci of disease allowed the development of breast 
conservation therapy (BCT). With the emergence of BCT, 
women with invasive breast cancer may now preserve their 
breast without compromising the oncological outcome. Sev-
eral prospective randomized clinical trials have demonstrated ClinicoEconomics and Outcomes Research 2010:2 49
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equivalent survival outcome between mastectomy and BCT.20–
24 The absolute contraindications for BCT include a history 
of prior therapeutic RT, which would result in an excessively 
high total radiation dose to the chest wall; multicentric disease 
(two or more primary tumors in separate quadrants of the 
breast); and diffuse, malignant-appearing microcalcifications 
on mammography. Pregnancy is an absolute contraindication 
to the use of breast irradiation: however, it may be possible 
to perform breast-conserving surgery in the third trimester, 
deferring breast irradiation until after delivery. Relative 
contraindications to BCT include connective tissue disease, 
which results in poor tolerance of RT, and a sizeable tumor 
in a smaller breast where the subsequent cosmetic outcome 
would be unacceptable.
Axillary lymph node dissection (ALND) has traditionally 
been standard practice in the surgical management of early 
breast cancer. The benefits of ALND include its impact on 
disease control (ie, axillary recurrence and survival), while 
it also has significant prognostic value and plays an impor-
tant role in treatment selection. Histological examination of 
removed lymph nodes at the time of ALND is thought to be 
the most accurate method for assessing the spread of disease 
to these nodes. In order to avoid the negative impact of ALND 
on quality of life, the sentinel lymph node (SLN) technique has 
been developed. This technique is increasingly being used as 
a method to determine whether full ALND is necessary. For 
patients who undergo SLN biopsy rather than initial ALND, 
completion ALND continues to be the standard treatment rec-
ommendation if the SLNs are positive.25 The SLN technique 
should not be used in women with palpable axillary lymph 
nodes and in patients with inflammatory breast cancer.
Table 1 (Continued)
FEC followed by paclitaxel101
5-Fluorouracil 600 mg/m2 day 1
Epirubicin 90 mg/m2 day 1
Cyclophosphamide 600 mg/m2 day 1
Every 21 days, for three cycles followed by paclitaxel 100 mg/m2 weekly 
for eight weeks
CMF regimen
Cyclophosphamide 100 mg/m2, po, days 1–14
Methotrexate 40 mg/m2 days 1 and 8
5-Fluorouracil 600 mg/m2 days 1 and 8
Every 28 days, for six cycles
Abbreviations: TAC, docetaxel-doxorubicin-cyclophosphamide; AC, doxorubicin-
cyclophosphamide; AT, doxorubicin-docetaxel; TC, docetaxel-cyclophosphamide; EC, 
epirubicin-cyclophosphamide; FAC, 5-fluorouracil-doxorubicin-cyclophosphamide; FEC, 
5-fluorouracil-epirubicin-cyclophosphamide; CMF, cyclophosphamide-methotrexate-
5-fluorouracil; po, oral.
Table 1 Preferred regimens for the adjuvant treatment of early 
breast cancer
TAC regimen88
Docetaxel 75 mg/m2 day 1
Doxorubicin 50 mg/m2 day 1
Cyclophosphamide 500 mg/m2 day 1
Every 21 days for six cycles
AC regimen89
Doxorubicin 60 mg/m2 day 1
Cyclophosphamide 600 mg/m2 day 1
Every 21 days for four cycles
AC followed by paclitaxel regimen90–92
Doxorubicin 60 mg/m2 day 1
Cyclophosphamide 600 mg/m2 day 1
Every 21 days for four cycles followed by paclitaxel 175 mg/m2 weekly 
for 12 weeks
Dose-dense AC followed by paclitaxel93
Doxorubicin 60 mg/m2 day 1
Cyclophosphamide 600 mg/m2 day 1
Every 14 days for four cycles followed by paclitaxel 175 mg/m2 day 1 
every 14 days for four cycles
AT regimen94
Doxorubicin 60 mg/m2 day 1
Docetaxel 60 mg/m2 day 1
Every 21 days, for four cycles
TC regimen95
Docetaxel 75 mg/m2 day 1
Cyclophosphamide 600 mg/m2 day 1
Every 21 days, for four cycles
EC regimen96
Epirubicin 100 mg/m2 day 1
Cyclophosphamide 830 mg/m2 day 1
Every 21 days, for eight cycles
FAC regimen97,98
5-Fluorouracil 500 mg/m2 days 1 and 8
Doxorubicin 50 mg/m2 day 1
Cyclophosphamide 500 mg/m2 day 1
Every 21 days, for six cycles
FEC regimen99
5-Fluorouracil 500 mg/m2 days 1 and 8
Epirubicin 60 mg/m2 days 1 and 8
Cyclophosphamide 75 mg/m2, po, days 1–14
Every 21 days for six cycles
FEC followed by docetaxel100
5-Fluorouracil 500 mg/m2 day 1
Epirubicin 100 mg/m2 day 1
Cyclophosphamide 500 mg/m2 day 1
Every 21 days, for three cycles followed by docetaxel 100 mg/m2 day 1 
every 21 days for three cycles
(Continued)ClinicoEconomics and Outcomes Research 2010:2 50
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Hormonal treatment
For patients with hormone receptor-positive tumors, 
hormonal treatment is one of the first choices for treatment.6,26 
Hormonal therapy acts by depriving the tumor cells of the 
proliferative stimulus provided by estrogen. This can be 
achieved by blocking the binding of estrogen to its receptor 
in the nucleus of responsive cells, as with tamoxifen. In 
premenopausal women, estrogens are directly produced in 
the ovaries until production declines during the menopause. 
After the menopause, estrogens are still produced (to a lesser 
extent) in nonovarian tissues, such as muscle and fat, by the 
enzyme aromatase, which converts androgens secreted by 
the adrenal cortex into estrogens. Aromatase inhibitors block 
the conversion of androgens to estrogens in the peripheral 
tissues in postmenopausal women, thereby reducing plasma 
levels of estrogens.27
Given the high incidence of estrogen receptor-positive 
breast cancer, it is clear that advances in endocrine treat-
ment have the potential to result in significant decreases 
in breast mortality. Tamoxifen is one of the most studied 
agents in the treatment of estrogen receptor-positive breast 
cancer in both adjuvant and advanced disease settings. 
Tamoxifen provides protection against bone fractures in 
postmenopausal women and also lowers serum cholesterol 
levels. However, the long-term use of tamoxifen may be 
associated with vaginal bleeding, endometrial thickening, 
and increased risk of endometrial cancer and thromboem-
bolic events.
Although tamoxifen has been the backbone of hormonal 
treatment for both pre- and postmenopausal women,28,29 
several randomized Phase III trials have evaluated the role 
of aromatase inhibitors in women with hormone receptor-
positive breast cancers, either in the adjuvant30–41 or in 
the advanced42–46 disease setting. Although it is clear that 
aromatase inhibitors offer a significant benefit in terms of 
disease-free survival when compared with tamoxifen, it is 
not clear which approach is the most effective, ie, initial 
use of aromatase inhibitors, sequential use after 2–3 years 
of tamoxifen, or extended use after five years of tamoxifen. 
Although cross-study comparisons have severe limitations, 
trials evaluating the sequential approach report a hazard ratio 
ranging from 0.57 to 0.76, while the upfront approach results 
in a hazard ratio of 0.82–0.87. Thus, one could argue that 
the sequential approach is more effective. Although upfront 
trials do not report a survival benefit in favor of aromatase 
inhibitors, a pooled analysis of the ARNO 95, ABCSG 8, 
and ITA trials reported a survival benefit for the sequential 
approach.47
Chemotherapy
Chemotherapy is used in the treatment of both hormone recep-
tor-positive and -negative patients in the adjuvant and advanced 
disease settings. Chemotherapy offers benefits in terms of 
symptom control, quality of life, and survival, and is consid-
ered the treatment of choice for many patients. However, it 
is also associated with significant toxicity. A number of dif-
ferent chemotherapy drugs, or classes of drug, are effective, 
including anthracyclines (doxorubicin, epirubicin), taxanes 
(docetaxel and paclitaxel), capecitabine, vinorelbine, gem-
citabine, alkylating agents such as cyclophosphamide, and 
platinum-based drugs such as carboplatin.
Adjuvant chemotherapy
Adjuvant chemotherapy should be considered after definitive 
surgical treatment. The published results of the Early Breast 
Cancer Trialists’ Collaborative Group overview analysis have 
clearly demonstrated that adjuvant polychemotherapy results in 
substantial reductions in the risk of recurrence and death from 
breast cancer in all age groups under the age of 70 years.6 The 
decision whether or not to administer adjuvant chemotherapy 
should take into account the estimated absolute benefit, the 
patient’s life expectancy, the presence or absence of prognostic 
factors, treatment tolerance, and patient preferences.
A number of prognostic factors have been associated 
with the risk of recurrence or death from breast cancer. The 
strongest prognostic factors are the patient’s age, tumor 
size, tumor grade, number of lymph nodes involved, Her-2 
status, peritumoral vascular invasion, and hormonal receptor 
status.26,27 The absolute benefit of chemotherapy therefore 
varies according to both the patient’s age and underlying 
prognostic factors.
According to the National Comprehensive Cancer Network 
(NCCN) guidelines,48 patients with lymph node involvement or 
with tumors greater than 1 cm in diameter are appropriate can-
didates for adjuvant systemic therapy. On the other hand, the 
St Gallen International Expert Consensus takes into account 
all the above-mentioned prognostic factors in order to recom-
mend adjuvant chemotherapy or not.26 Furthermore, recent 
advances in DNA microarray technologies has allowed the 
development of classification systems of breast cancer by gene 
expression profile.49 Five major subtypes of breast cancer have 
been identified by DNA gene expression profiling: estrogen 
receptor-positive/Her-2 negative (luminal A and luminal B 
subtypes); estrogen receptor-negative/Her-2 negative (basal 
subtype); Her-2 positive; and normal breast-like tumors.49 In 
retrospective analyses, these profiles were found to be asso-
ciated with the risk of relapse and death from breast cancer. ClinicoEconomics and Outcomes Research 2010:2 51
Pharmacoeconomic considerations in breast cancer Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
This approach could possibly be used for decision-making in 
adjuvant treatment of breast cancer patients, but it needs to 
be validated prospectively.
Despite the high incidence of breast cancer and the 
extensive research in this field, no chemotherapy regimen can 
be considered as “standard” treatment for early breast cancer. 
Preferred adjuvant regimens according to NCCN guidelines 
are presented in the Table.48 Allocation to about six months of 
anthracycline-based polychemotherapy (eg, with fluorouracil-
doxorubicin-cyclophosphamide or fluorouracil-epirubicin-
cyclophosphamide) reduces the annual breast cancer death 
rate by about 38% for women younger than 50 years when 
diagnosed and by about 20% for those aged 50–69 years 
when diagnosed, largely irrespective of the use of tamoxifen 
and of estrogen receptor status, nodal status, or other tumor 
characteristics. Such regimens are significantly (P = 0.0001 
for recurrence, P  0.00001 for breast cancer mortality) more 
effective than cyclophosphamide-methotrexate-5-flurouracil 
chemotherapy.6 Similarly, the inclusion of taxanes in the 
adjuvant treatment of breast cancer resulted in a 17% 
reduction in the risk of relapse (P  0.00001) and a 15% 
reduction in the risk of death (P  0.00001) compared with 
taxane-free regimens.50
Advanced disease
Compared with the treatment options for early-stage 
breast cancer, few data exist regarding the optimal use of 
chemotherapy for metastatic breast cancer (MBC). A variety 
of chemotherapy agents, either as single-agent or combina-
tion regimens, are considered effective in the treatment of 
MBC: anthracyclines (doxorubicin, epirubicin, liposomal 
doxorubicin), taxanes (paclitaxel, docetaxel), antimetabolites 
(gemcitabine, capecitabine), and microtubule inhibitors 
(vinorelbine). A significant but still controversial issue in 
the treatment of MBC remains the choice between using a 
combination of cytotoxic chemotherapies or sequential single 
agents.51 Combination regimens result in higher response 
rates and a longer time to tumor progression (TTP) compared 
with sequential single agents; however, they do not offer 
substantial survival benefit.52,53 Furthermore, combination 
treatment is associated with significantly higher toxicity and 
adverse events.54 On the basis of available data, sequential 
monotherapy is recommended as the preferred choice in 
advanced disease, in the absence of rapid clinical progression, 
life-threatening visceral metastases, or the need for rapid 
symptom and/or disease control.48,51
A recently published study randomly allocated 715 women 
with MBC to first-line chemotherapy with paclitaxel with 
or without bevacizumab, a humanized monoclonal antibody 
against vascular endothelial growth factor.55 This trial yielded 
a significant prolongation of TTP in favor of bevacizumab, 
but failed to show a statistically significant difference in 
terms of overall survival.
Trastuzumab in Her-2 positive disease
Her-2/neu is a member of the erb family and is a proto-oncogene 
located on chromosome 17q21. Approximately 18% to 20% 
of breast cancers have amplification and/or overexpression 
of this gene, which encodes the cell surface molecule HER2, 
a transmembrane glycoprotein receptor with tyrosine kinase 
activity.56 Trastuzumab (Herceptin, Genentech, Roche) is a 
recombinant DNA-derived, chimeric, humanized monoclonal 
antibody that binds to the extracellular domain of Her-2.
Patients with Her-2 positive MBC should receive treat-
ment with trastuzumab, either in combination with cytotoxic 
chemotherapeutic agents57–60 or as single agent.61 Patients 
with Her-2 positive MBC should continue anti-Her treat-
ment after progression on first-line trastuzumab-containing 
regimens. Patients could continue trastuzumab following 
progression on trastuzumab-containing regimens, given that 
several trials have demonstrated a benefit.62,63 A recent Phase 
III trial demonstrated that the combination of lapatinib with 
capecitabine in patients with MBC refractory to trastuzumab 
offers a significant prolongation of TTP compared with 
capecitabine alone.64 Additionally, in heavily pretreated 
women with MBC refractory to trastuzumab, the combina-
tion of trastuzumab plus lapatinib resulted in a longer TTP 
compared with lapatinib monotherapy.65
Five randomized Phase III trials evaluated the role 
of trastuzumab in combination with chemotherapy as 
adjuvant treatment in early breast cancer.66–69 All these trials 
demonstrated a statistically significant reduction in the risk of 
relapse and some of them also reported a survival benefit.66,67 
On the basis of these trials trastuzumab is recommended 
for Her-2 positive tumors 1 cm.48 It is not clear whether 
trastuzumab should be administered for one year66,67,69 or for 
a shorter period on the basis of the FinHer trial.68
Metastatic bone disease
Metastatic bone disease is one of the most common 
metastases in breast cancer. Breast cancer patients 
with bone metastatic disease should be treated with 
bisphosphonates.70 Bisphosphonate treatment is associated 
with fewer skeletal-related events, pathological fractures, 
and less need for radiation treatment and surgery to treat 
bone pain.71–73 Bisphosphonate treatment is given in addi-ClinicoEconomics and Outcomes Research 2010:2 52
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tion to chemotherapy or hormonal therapy, but it should be 
underlined that bisphosphonate is a palliative measure and 
does not offer a survival benefit.
Adverse effects
Hot flushes are a common side effect of both tamoxifen and 
aromatase inhibitors, although they occur more frequently 
in patients receiving aromatase inhibitors.29 Arthralgias are 
also more frequent in patients receiving aromatase inhibitors 
compared with tamoxifen and their incidence ranges from 
18% to 36% in clinical trials.29 However, the mechanism 
by which arthralgias are created is not clearly understood. 
Furthermore, studies designed to look at the effect of aro-
matase inhibitors on bone mineral density have shown a 
significant decrease in bone mineral density in the aromatase 
inhibitor groups compared with placebo groups and hence 
an increase in the incidence of fractures in comparison 
with tamoxifen.74 With respect to cardiovascular disease, 
although tamoxifen is considered to be cardioprotective, it 
is not clear whether aromatase inhibitors are associated with 
a higher incidence of cardiovascular events. The BIG 1–98 
study reported an increase in cardiovascular events com-
pared with tamoxifen,32 while the MA.17 study reported 
no difference.75
Adjuvant treatment with a combination of trastu-
zumab and chemotherapy has been associated with a sig-
nificant increase in the risk of congestive heart failure and 
arrhythmias.76,77 In the above-mentioned trials, the percentage 
of severe (Class III/IV) congestive heart failure, or cardiac-
related death for patients receiving trastuzumab ranged from 
0% (59) to 4.1%.77 Additionally, concerns have been raised 
about the long-term cardiac risks in patients receiving trastu-
zumab, based on a longer followup.78
Brain metastases are increasingly being reported as the 
site of first relapse in women with breast cancer who are 
receiving trastuzumab for Her-2-overexpressing disease. 
A trend towards a higher number of central nervous system 
metastases as the first event in the trastuzumab-containing 
arms has been reported for the N9831/NSABP B-3166 and 
HERA67 trials. However, it seems unlikely that the use of 
trastuzumab in the adjuvant setting “increases” the risk of 
brain metastases.79 It is more likely that the central nervous 
system represents a sanctuary site due to the inability of 
trastuzumab to cross the blood-brain barrier.
Economic analysis
In order to evaluate the cost-effectiveness of the various 
approaches to the treatment of breast cancer, we undertook 
a literature review of recently published studies evaluating 
the aforementioned therapies. The terms “breast cancer” and 
“cost” were used as key words in the various databases. The 
search was limited to articles published from 1999 to 2009 
and included only English language studies. Studies which 
evaluated the cost-effectiveness of screening programs, 
diagnostic techniques, and effectiveness of alternative treat-
ments were excluded from the review. Studies that had not 
undertaken an original economic evaluation and reported 
results from literature reviews only were also excluded. The 
remaining studies were classified into two categories, ie, those 
that reported the economic burden of the disease and those 
that evaluated the cost-effectiveness of the treatments. The 
pharmacoeconomic evaluations were classified based on the 
substance used for treatment.
Overall, the majority of the studies present unanimity 
regarding the methodology followed. Cost-effectiveness 
analysis and the development of a Markov model were 
the most popular methodologic approaches in the studies 
reviewed. Quality-adjusted life years (QALYs) and life 
years gained (LYG) were the preferred measures of benefit, 
while the majority of the studies were carried out under the 
third-party payer or health system perspective. All studies 
performed a sensitivity analysis in order to investigate the 
robustness of their results. The parameters that seem to be the 
most influential are the time horizon, stage of the disease, age 
of the patient, as well as time of therapy initiation, duration 
of benefits and time to recurrence.
Cost-effectiveness of drug therapy
Tamoxifen
Tamoxifen is used for both the prevention and the treatment 
of breast cancer. The use of tamoxifen therapy over a five-year 
period has been proved to be cost-effective regarding breast 
cancer risk reduction. The incremental cost per QALY gained 
was Aus$38,271.80 A cost-utility analysis compared tamoxi-
fen with tamoxifen plus chemotherapy as adjuvant therapy in 
postmenopausal women with early breast cancer in the UK. 
Tamoxifen plus chemotherapy was more effective but at the 
same time more expensive compared with tamoxifen alone. 
The incremental cost per QALY gained was £3,483, indicat-
ing that the combination of tamoxifen with chemotherapy 
was cost-effective.81
Aromatase inhibitors
The majority of the pharmacoeconomic evaluations identified 
in our review concerned aromatase inhibitors, both non-
steroidal (anastrozole, letrozole) and steroidal (exemestane). ClinicoEconomics and Outcomes Research 2010:2 53
Pharmacoeconomic considerations in breast cancer Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Assessment of sequential use of exemestane after two or 
three years of tamoxifen in postmenopausal women with 
early-stage breast cancer was the main objective in several 
economic evaluations. Even though the time horizon of the 
studies was different, as was the currency used, the conclusion 
was the same in all studies, and demonstrated that sequential 
treatment with exemestane was cost-effective. The incremen-
tal cost per QALY gained was estimated at US$20,100 in the 
USA,82 Can$24,185 in Canada,83 and ¤20,000 in Sweden.84
In the case of advanced breast cancer the use of 
exemestane instead of megestrol was cost-effective. In 
the US the incremental cost per LYG was US$10,60085 
while in Europe it was ranged from ¤3,700 in Germany to 
¤9,091 in the Netherlands.86 Similarly, letrozole represents 
a cost-effective alternative to megestrol in the UK National 
Health Service (NHS) setting, with an incremental cost per 
LYG of £3,588.87
Chemotherapy
Taxanes are a therapeutic class used in chemotherapy. 
Taxanes can be administered as single agents or in combina-
tion with other taxanes, antimetabolites, or anthracyclines.
A recent economic evaluation of the cost-effectiveness of 
taxanes in the adjuvant treatment of breast cancer reported a 
cost per QALY for taxane compared with nontaxane-containing 
chemotherapy of £12,000–£43,000, depending on the taxane 
under consideration and the specific trial used as the basis of 
the analysis.88 A cost-utility analysis in Thailand assessed the 
cost effectiveness of doxorubicin-cyclophosphamide adjuvant 
therapy versus cyclophosphamide-paclitaxel in women with 
early-stage breast cancer. Although the estimated benefits 
for the patient were better in the case of the combination 
therapy, the incremental cost per QALY was THB738,111 
(∼US$22,250), thus prohibiting the implementation of this 
therapy in Thailand.89
In the UK in 2001, a Markov model was designed to assess 
the cost-utility ratios of three different taxanes in patients 
with advanced breast cancer.90 Docetaxel was the most cost-
effective treatment compared with paclitaxel and vinorel-
bine. The incremental cost for docetaxel per QALY gained 
was £1,995 over paclitaxel and £14,055 over vinorelbine. 
A similar study was carried out in Canada, where the study 
population was patients with metastatic breast cancer. The 
average cost per quality-adjusted progression-free survival 
ranged from Can$31,220 for vinorelbine to Can$110,072 for 
docetaxel.91 A more recent study of the cost-effectiveness of 
docetaxel over paclitaxel for the treatment of MBC patients 
reported that docetaxel was a cost-effective therapy, with an 
incremental cost per LYG of Can$30,337.92 Another study 
compared taxanes with standard second-line chemotherapy 
in patients with MBC. The cost-utility analysis showed that 
the cost per QALY ranged from US$13,922 for standard 
chemotherapy to US$49,739 for docetaxel. The authors 
reported that, although current chemotherapy was the cheap-
est approach, it offered the least number of LYG. Thus, the 
best alternative was vinorelbine-mytomycin C therapy.93
A common therapeutic scheme in chemotherapy is the 
combination of taxanes with antimetabolites, and espe-
cially the use of capecitabine combined with docetaxel 
as therapy for the treatment of MBC. In our review, three 
different studies evaluating this treatment scheme in com-
parison with single-agent taxane therapy were identified 
and they reported that the combination therapy was cost-
effective in the treatment of MBC.94–96 A Markov model 
was developed to estimate the cost-effectiveness of gem-
citabine-paclitaxel in patients with MBC and reported an 
incremental cost-effectiveness ratio (ICER) of £38,699 per 
QALY gained, which is higher than the threshold defined 
by the NHS.97
Despite the high incidence of breast cancer and the 
great amount of data in the field of first-line therapy, limited 
economic evidence is available about the cost-effectiveness 
of the various treatment options presented. An economic 
evaluation for first-line sequential therapy was reported by 
the National Institute for Health and Clinical Excellence 
(NICE).98 The scenario studied considered that all patients 
would have been treated with anthracyclines in the adjuvant 
setting. The analysis showed that the most cost-effective 
treatment sequence, based on a threshold of £30,000 per 
QALY, was docetaxel monotherapy followed by capecitabine 
monotherapy followed by vinorelbine monotherapy. The 
ICER for this sequence was estimated to be £23,332 per 
QALY. When applying a threshold of £20,000 per QALY, 
the most cost-effective sequence was docetaxel monotherapy 
followed by capecitabine monotherapy, followed by no further 
chemotherapy.
Trastuzumab
A recently published systematic review evaluated the 
cost-effectiveness of adjuvant trastuzumab treatment.99 
Cost-effectiveness ratios reported ranged from US$5,020/
QALY to US$134,610/QALY. Most studies reported 
favorable cost-effectiveness values (ie, below US$50,000/
QALY). About 84.6% were conducted using a Markov 
model based on data from clinical trials and 15.3% were 
analyzed by other economic or cost models; 84.6% reported ClinicoEconomics and Outcomes Research 2010:2 54
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sensitivity analysis, 11 studies (84.6%) clearly described a 
justification for selecting the study design, and only 15.3% 
noted study limitations. A NICE guideline evaluated all the 
available data for trastuzumab adjuvant studies and esti-
mated incremental costs per QALY gained with adjuvant 
trastuzumab treatment ranging from £16,000 to £33,000.100 
A cost-effectiveness analysis reported by Belgian health 
care authorities estimated the incremental cost-effective-
ness ratio based on a lifetime simulation at ¤10,315 per 
QALY gained.101
The cost-effectiveness of trastuzumab in combination 
with standard treatment in HER-2 positive breast cancer 
patients was estimated in several studies identified in our 
review. The economic results and benefits differ based on the 
stage of the disease. However, both clinical and economic 
benefits were superior for the stage III patients.102 The authors 
of a Belgian study found that nine weeks of trastuzumab was 
dominant over no trastuzumab treatment.102 Similar results 
were reported by the authors of an Australian study, who 
found that nine weeks’ trastuzumab was dominant over no 
trastuzumab, reporting an incremental cost of Aus$1,700 per 
QALY gained for nine-weeks of trastuzumab compared with 
standard treatment alone.103
Bisphosphonates
Our review identified seven economic evaluations of 
bisphosphonates as a treatment intervention in metastatic 
bone disease. The majority of these studies compared 
third-generation bisphosphonates (zoledronic acid, 
ibandronate) with second-generation (pamidronate) or 
first-generation (clodronate) bisphosphonates. An eco-
nomic study conducted in the UK compared five types 
of bisphosphonates with no treatment from the NHS per-
spective. According to the findings of the study, the use of 
bisphosphonates in the management of patients with bone 
metastases was cost-saving to the NHS. In fact, zoledronic 
acid was the dominant strategy of all the five types com-
pared in the study.104
Two different studies assessed the economic conse-
quences of zoledronic acid versus pamidronate as the 
therapeutic strategy in patients with at least one bone 
metastasis. The perspective of both studies was the health 
system, but the results were different. The first study was 
carried out in the UK and concluded that pamidronate 
was the preferred strategy because it could lead to a 
reduction of 11% in health care costs.105 The second was 
undertaken in Spain and the conclusion was that, although 
zoledronic acid was more expensive, its higher cost could 
be counterbalanced by the savings in infusion time and 
better outcomes.106
In the case of breast cancer patients who suffer from 
bone metastases and are concurrently undergoing oral 
hormonal therapy, oral ibandronate is the dominant treatment 
option compared with zoledronic acid and pamidronate.107 
On the other hand, there are studies that, although agree-
ing that bisphosphonates (especially third-generation 
bisphosphonates108) are effective in the secondary prevention 
of bone complications in breast cancer metastases, conclude 
either that this strategy is too expensive109 or that the cost of 
providing it will be large given the prevalence of metastatic 
breast cancer.110
Overall, the costs of bisphosphonate therapy appear 
to be higher than the cost savings from the prevention of 
skeletal-related events. The costs per QALY have been esti-
mated to be US$100,000.111
Aromatase inhibitors  
versus tamoxifen
Adjuvant setting
Postmenopausal
In postmenopausal women, the standard of care for hormone 
receptor-positive tumors was five years of tamoxifen. This 
approach was associated with a 40% reduction in the risk 
of recurrence and 34% reduction in the risk of death.6 Until 
recently, trials testing durations of tamoxifen longer than 
five years had not shown additional benefit, but the ATLAS 
(Adjuvant Tamoxifen, Longer Against Shorter) trial, showed 
a small but significant reduction in the risk of recurrence with 
10 years compared with five years of tamoxifen therapy.112
However, during the last decade tamoxifen’s role has been 
challenged by the aromatase inhibitors, namely letrozole, 
anastrozole (nonsteroidal) and exemestane (steroidal). In early 
breast cancer, and especially in postmenopausal women with 
hormone receptor-positive cancer, initial adjuvant therapy with 
letrozole was found to be cost-effective compared with tamoxi-
fen, with an incremental cost per QALY of Can$23,662.113 
Letrozole can be used as first-line therapy for advanced breast 
cancer and it is a cost-effective option. This was suggested 
by two different studies evaluating the costs and benefits of 
this treatment scheme. The first was carried out in Japan and 
showed a cost of US$4,969 per LYG over tamoxifen,114 while 
the second yielded a cost per LYG of £5,917.115
Similar results were reported from pharmacoeconomic 
studies investigating the cost-effectiveness of the use of 
anastrozole over tamoxifen in different countries. Even ClinicoEconomics and Outcomes Research 2010:2 55
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though the currency used was different, the conclusion 
was that anastrozole is a cost-effective choice as adjuvant 
therapy for early breast cancer.116–120 The use of letrozole 
in the extended adjuvant treatment was also proved to be 
cost-effective, yielding an ICER of Can$34,058 per QALY 
in Canada121 and US$28,728 per QALY in the US.122
Three different approaches have been tested against the 
“gold standard” of five years of tamoxifen, ie, upfront aro-
matase inhibitors, two to three years of tamoxifen followed 
by aromatase inhibitors for a total of five years, and extended 
treatment with sequential aromatase inhibitors after five years 
of tamoxifen.
Two large Phase III trials with more than 17,000 patients 
evaluated anastrozole30,31 and letrozole32 for five years versus 
five years of tamoxifen, and both studies demonstrated an 
improvement in disease-free survival in favor of aromatase 
inhibitors (hazards ratio [HR] for anastrozole: 0.87, 95% CI 
0.78–0.97; P = 0.01; HR for letrozole: 0.82, 95% CI 0.71–0.95; 
P = 0.007). However, both studies failed to yield any differ-
ence in overall survival. Interestingly, the letrozole trial (BIG 
1-98 trial) also evaluated the sequential approach (2–3 years 
of tamoxifen followed by letrozole for a total of five years or 
three years letrozole upfront followed by tamoxifen for a total 
of five years), but data from these arms are not yet available.
A randomized Phase III trial randomized 4,724 patients 
to exemestane after 2–3 years of tamoxifen or to continue 
tamoxifen for a total of five years34 and demonstrated a sig-
nificant prolongation of progression-free survival in favor of 
exemestane (HR: 0.76, 95% CI 0.66–0.88; P = 0.0001).33,34 
Similarly, a combined analysis of the Austrian Breast and 
Colorectal Cancer Study Group (ABCSG) trial 8 and the 
Arimidex-Nolvadex (ARNO 95) trial revealed a significant 
40% reduction in the risk of relapse when anastrozole was 
administered after two years of tamoxifen, compared with 
five years of tamoxifen (HR: 0.60, 95% CI 0.44–0.81; 
P = 0.0009).35 Finally, a smaller Italian study demonstrated 
a statistically significant benefit in terms of progression-free 
survival in favor of the switching strategy.36,37
The National Cancer Institute of Canada (NCIC) MA 
17 trial randomized 5,187 patients to letrozole for five years 
or to placebo, after completion of five years of tamoxifen.39,75 
The study was terminated early, when a planned interim 
analysis demonstrated a significant improvement in disease-
free survival in favor of letrozole, which was confirmed after a 
longer followup (HR: 0.58, 95% CI 0.45–0.76; P  0.0001)75 
Likewise, a study from the National Surgical Adjuvant Breast 
and Bowel Project B-33 study asked a similar question using 
exemestane and revealed a trend towards higher four-year 
progression-free survival in favor of exemestane (HR: 0.68, 
P = 0.07).40 Finally, an ABCSG trial tested extended treatment 
with three years of anastrozole in approximately 900 patients 
and revealed a borderline statistically significant improve-
ment in disease-free survival in favor of extended treatment 
(HR: 0.64, 95% CI 0.41–0.99; P = 0.048).38
A detailed economic analysis evaluated these three differ-
ent therapeutic approaches in terms of QALYs gained versus 
tamoxifen (or placebo in the case of extended therapy after 
five years of tamoxifen).123 The analysis used a state transition 
model (Markov) approach to simulate the disease outcomes 
of patients up to a time horizon of 35 years post-surgery. 
The cost-effectiveness results when anastrozole or letrozole 
were used upfront versus tamoxifen were estimated to be 
£32,000 and £21,600 per QALY, respectively. In the case of 
the sequential strategy, data are available only for anastrozole 
and exemestane. (As mentioned above, the BIG 1-98 trial, 
which is evaluating the sequential approach for letrozole, 
has not yet published results for the sequential arm.) The 
cost-effectiveness results for the sequential approach were 
estimated to be £23,200 and £19,200 per QALY for anastro-
zole and exemestane, respectively. Finally, in the extended 
adjuvant setting, data were available only for letrozole and 
the cost per QALY was calculated to be £9,800.
In these estimations it was assumed that the benefit of 
aromatase inhibitors observed during the study period was 
gradually lost during the following 10 years (meaning that it 
was assumed that after the study period the recurrence rate 
would be significantly higher for aromatase inhibitors com-
pared with tamoxifen and that at year 15 the number of patients 
without disease recurrence would be similar in the aromatase 
inhibitor and tamoxifen arms). When an alternative scenario 
with “benefits maintained” was tested, the cost-effectiveness 
was reduced by almost 50% to approximately £10,000–12,000, 
£5,000 and £3,000 for the upfront, sequential, and extended 
approaches, respectively.123
Premenopausal
Concerning premenopausal women, the optimal management 
of endocrine-responsive early breast cancer remains 
controversial. Tamoxifen is the gold standard for hormone 
receptor-positive early breast cancer.28 Oophorectomy 
with either ablation or suppression using a luteinising 
hormone-releasing hormone (LHRH) analog results in a 
reduction of approximately 30% in breast cancer recurrence 
and mortality.6 The combination of ovarian suppression with 
the use of LHRH analogs and tamoxifen is a widely used 
approach; however, it is not clear whether this combination ClinicoEconomics and Outcomes Research 2010:2 56
Pallis et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
offers a benefit compared with tamoxifen alone.6,124 Although 
aromatase inhibitors have shown benefits superior to those 
of tamoxifen in postmenopausal women,19 their benefits in 
premenopausal women are unknown. In premenopausal 
women, the use of aromatase inhibitors leads to an increase 
in gonadotropin secretion, because of the reduced feedback 
of estrogens to the hypothalamus and pituitary, and a 
subsequent stimulation of ovarian activity.27 The combina-
tion of aromatase inhibitors with a GnRH analog can achieve 
complete estrogen blockade by suppression of ovarian func-
tion and of peripheral estrogen synthesis.27
A recently published Phase III trial evaluated the role of 
LHRH combined with either tamoxifen or anastrozole as 
adjuvant treatment in 1803 premenopausal women.41 Patients 
were also randomized to receive zoledronic acid or not. 
The primary endpoint of the trial was disease-free survival. 
There was no significant difference in disease-free survival 
between the anastrozole and tamoxifen groups (HR: 1.10, 
95% CI 0.78–1.53; P = 0.59). In contrast, the addition of 
zoledronic acid to endocrine therapy, as compared with 
endocrine therapy without zoledronic acid, resulted in an 
absolute reduction of 3.2 percentage points and a relative 
reduction of 36% in the risk of disease progression (HR: 
0.64, 95% CI 0.46–0.91; P = 0.01). The small amount of 
data available about the role of aromatase inhibitors in 
the adjuvant treatment of premenopausal women and the 
small followup period preclude the drawing of any solid 
conclusions. Additionally, no pharmacoeconomic data exist 
concerning this approach. However, given the fact that the 
above-mentioned study yielded no difference between the 
two arms in terms of disease-free survival or toxicity, and 
given that anastrozole is more expensive than tamoxifen, a 
cost-minimization analysis would likely yield tamoxifen as 
the treatment of choice.
Advanced disease setting
Postmenopausal
Tamoxifen has until recently been considered the drug of 
choice for first-line endocrine therapy in postmenopausal 
women, due to its efficacy and low toxicity. However, a 
number of Phase III studies have demonstrated that aroma-
tase inhibitors are superior to tamoxifen as first-line therapy 
in postmenopausal women with advanced breast cancer.42–46 
Although a meta-analysis of published randomized trials 
demonstrated a progression-free survival benefit (HR: 0.78, 
95% CI 0.70–0.86), there was no overall survival benefit.125 
In the second-line setting, anastrozole, letrozole, and exemes-
tane have all been shown to offer efficacy and tolerability 
advantages over megestrol acetate, the previous standard 
second-line endocrine therapy, in tamoxifen-resistant patients 
with hormone-dependent advanced breast cancer.126–129 On the 
basis of these trials, aromatase inhibitors are recommended 
for postmenopausal women with estrogen receptor-positive 
breast cancer who have not previously received endocrine 
treatment or who have been previously treated with tamoxi-
fen. For postmenopausal women who are antiestrogen naïve 
or who have relapsed more than one year after previous 
treatment, aromatase inhibitors appear to have superior out-
comes compared with tamoxifen, although the differences 
are modest.
Results of the economic analysis indicate that letrozole 
is a cost-effective alternative first-line therapy compared 
with tamoxifen for postmenopausal women with advanced 
breast cancer, achieving additional life-years with a modest 
increase in costs, having a mean incremental cost per LYG of 
£2,342.130 The incremental costs in the comparison between 
letrozole or anastrozole and tamoxifen were below £5,075 
per LYG and £9,200 per QALY.131 Similarly, results obtained 
for letrozole, anastrozole, or exemestane when used as sec-
ond-line treatment versus megestrol revealed a maximum 
incremental cost-effectiveness ratio of £9,667 per LYG.
Premenopausal
The role of aromatase inhibitors in combination with an 
LHRH analog as first-line treatment has been evaluated in 
the context of Phase II trials.132,133 However, there is only 
limited experience and a small amount of data to draw on, 
and further research is needed before this treatment can 
generally be recommended.
Trastuzumab versus chemotherapy
In Italy, standard chemotherapy was compared with 
12-month adjuvant trastuzumab therapy. The incremental 
cost-utility ratio was ¤14,861 per QALY gained. Based on 
these results the conclusion was that in the long term trastu-
zumab is a cost-effective alternative.134 In Norway the study 
was carried out with a societal perspective. In a 10-year time 
horizon, the cost per QALY ranged from ¤10,185 to ¤37,862 
according to the overall improvement in survival. The authors 
suggested that trastuzumab may be cost-effective, provided 
that a minimum of 8% improvement in overall survival is 
accomplished.135
Conclusions
Significant progress has been made in the treatment of 
breast cancer during the last decade. Recent data support ClinicoEconomics and Outcomes Research 2010:2 57
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the use of aromatase inhibitors in the treatment of estrogen 
receptor-positive breast cancer, either in the adjuvant or in 
the advanced disease setting, at least for postmenopausal 
women, while for premenopausal patients data exist 
only for the adjuvant setting. Newer and more effective 
chemotherapy regimens have been tested in the early disease 
setting. Trastuzumab is a standard of care in the treatment 
of Her-2 positive disease, in either the adjuvant or advanced 
disease setting. Recently, bevacizumab has been proven to 
offer a benefit in combination with chemotherapy. Further-
more, pharmacoeconomic analysis yielded that. Despite 
their cost, these drugs are in general cost-effective, in 
various settings and countries, with incremental cost-effec-
tiveness ratios in line with those of many other reimbursed 
therapies.
However, a number of significant questions still remain 
unanswered. Which approach is the most effective in 
the adjuvant setting in postmenopausal women: up-front 
aromatase inhibitors, sequential, or extended after five years 
of tamoxifen? Could aromatase inhibitors in combination 
with LHRH analogs represent a “standard” option in 
premenopausal women in either the adjuvant or the advanced 
disease setting? Which is the “optimal” approach in the 
adjuvant treatment of early breast cancer? Is sequential 
chemotherapy a better approach than combination treatment 
in advanced disease? It is clear that prospective trials are 
needed to answer these questions. Many clinical trials are 
currently evaluating these research questions. It is hoped 
that one or more of these approaches will prove successful 
and lead to substantial progress in the treatment of this 
common and fatal disease. Pharmacoeconomic analyses of 
all alternative therapy options will improve decision-making 
and will help decision-makers to optimize the use of scarce 
health care resources allocated to the treatment of cancer 
and the care of patients.
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